title: A fast and simple approach for the simultaneous detection of hematopoietic chimerism, NPM1, and FLT3-ITD mutations after allogeneic stem cell transplantation.
abstract: Hematopoietic chimerism can be used as a tool for patient management after allogeneic hematopoietic stem cell transplantation (HSCT). An increase in the proportion of recipient cells after transplantation is strongly associated with relapse in chronic myeloid leukemia. However, in acute myeloid leukemia (AML) the significance of increasing mixed chimerism (MC) as a predictive marker for relapse is less clear. Several mutations frequently found in AML have been employed for minimal residual disease detection and relapse prediction. Therefore, a combined analysis of hematopoietic chimerism and of the molecular aberrations found in AML could be used to improve MC characterization. We developed a multiplex PCR for use in the simultaneous detection of hematopoietic chimerism and mutations in nucleophosmin (NPM1) and fms-like tyrosine kinase-3 internal tandem duplication (FLT3-ITD). A total of 303 samples from 20 AML patients were analyzed after HSCT. The microsatellite markers used for hematopoietic chimerism detection were D1S80, D7S1517, D4S2366, THO1, and SE33. A total of 149 samples from 18 patients showed MC with a mean detection time of 9.7 months. From the 18 patients with MC, in 6 of the patients, no FLT3-ITD or NPM1 mutation was found at any time point tested, and these patients remained in complete hematological remission. In 12 patients with MC, FLT3-ITD and NPM1 mutations were found, and these patients showed signs of hematological relapse. Our combined analysis of NPM1/FLT3-ITD mutations and hematopoietic chimerism improved the characterization of patients with MC after HSCT. The present approach may be further expanded by combining additional mutations found in AML with hematopoietic chimerism detection.
authors.affiliation: Department of Hematology and Oncology, University Medical Center Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany, miguel.waterhouse@uniklinik-freiburg.de.
authors.forename: Miguel
authors.initials: M
authors.lastname: Waterhouse
authors.forename: Hartmut
authors.initials: H
authors.lastname: Bertz
authors.forename: Juergen
authors.initials: J
authors.lastname: Finke
mesh_terms: D064591:Allografts; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000235:genetics / Q000628:therapy; D008297:Male; D008991:Monitoring, Physiologic / Q000379:methods*; D009154:Mutation; D009687:Nuclear Proteins / Q000097:blood / Q000235:genetics; D000090243:Nucleophosmin; D016133:Polymerase Chain Reaction / Q000379:methods; D018183:Transplantation Chimera / Q000097:blood / Q000235:genetics; D051941:fms-Like Tyrosine Kinase 3 / Q000097:blood / Q000235:genetics
chemical_list: C000716967:NPM1 protein, human; D009687:Nuclear Proteins; D000090243:Nucleophosmin; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3